Browsing by Author "Linde L."

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration
    (W.B. Saunders, 2022) Ørnbjerg L.M.; Linde L.; Georgiadis S.; Rasmussen S.H.; Lindström U.; Askling J.; Michelsen B.; Giuseppe D.D.; Wallman J.K.; Pavelka K.; Závada J.; Nissen M.J.; Jones G.T.; Relas H.; Pirilä L.; Tomšič M.; Rotar Z.; Geirsson A.J.; Gudbjornsson B.; Kristianslund E.K.; van sder Horst-Bruinsma I.; Loft A.G.; Laas K.; Iannone F.; Corrado A.; Ciurea A.; Santos M.J.; Santos H.; Codreanu C.; Akkoc N.; Gunduz O.S.; Glintborg B.; Østergaard M.; Hetland M.L.
    Objectives: In patients with axial spondyloarthritis (axSpA) initiating their first tumor necrosis factor alpha-inhibitor (TNFi), we aimed to identify common baseline predictors of Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) inactive disease (primary objective) and clinically important improvement (CII) at 6 months, and drug retention at 12-months across 15 European registries. Methods: Baseline demographic and clinical characteristics were collected. Outcomes were investigated per registry and in pooled data using logistic regression analyses on multiply imputed data. Results: The consistency of baseline predictors in individual registries justified pooling the data. In the pooled dataset (n = 21,196), the 6-month rates for ASDAS inactive disease and ASDAS CII were 26% and 51%, and the 12-month drug retention rate 65% in patients with available data (n = 9,845, n = 6,948 and n = 21,196, respectively). Nine common baseline predictors of ASDAS inactive disease, ASDAS CII and 12-month drug retention were identified, and the odds ratios (95%-confidence interval) for ASDAS inactive disease were: age, per year: 0.97 (0.97–0.98), men vs. women: 1.88 (1.60–2.22), current vs. non-smoking: 0.76 (0.63–0.91), HLA-B27 positive vs. negative: 1.51 (1.20–1.91), TNF start year 2015–2018 vs. 2009–2014: 1.24 (1.06–1.45), CRP>10 vs. ≤10 mg/l: 1.49 (1.25–1.77), one unit increase in health assessment questionnaire (HAQ): 0.77 (0.58–1.03), one-millimeter (mm) increase in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) fatigue and spinal pain: 0.99 (0.99–1.00) and 0.99 (0.99–1.99), respectively Conclusion: Common baseline predictors of treatment response and adherence to TNFi could be identified across data from 15 European registries, indicating that they may be universal across different axSpA populations. © 2022
  • No Thumbnail Available
    Item
    Corrigendum to ‘Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: data from the EuroSpA collaboration’ [Seminars in Arthritis and Rheumatism 56 (2022) 1-13/152081] (Seminars in Arthritis and Rheumatism (2022) 56, (S0049017222001329), (10.1016/j.semarthrit.2022.152081))
    (W.B. Saunders, 2023) Ørnbjerg L.M.; Linde L.; Georgiadis S.; Rasmussen S.H.; Lindström U.; Askling J.; Michelsen B.; Giuseppe D.D.; Wallman J.K.; Pavelka K.; Závada J.; Nissen M.J.; Jones G.T.; Relas H.; Pirilä L.; Tomšič M.; Rotar Z.; Geirsson A.J.; Gudbjornsson B.; Kristianslund E.K.; van der Horst-Bruinsma I.; Loft A.G.; Laas K.; Iannone F.; Corrado A.; Ciurea A.; Santos M.J.; Santos H.; Codreanu C.; Akkoc N.; Gunduz O.S.; Glintborg B.; Østergaard M.; Hetland M.L.
    The authors regret that the following incorrect values have been published in the original paper: In the abstract: Line 11-12: “age, per year: 0.97 (0.97-0.98)” should be “age, per year: 0.98 (0.97-0.99)” Line 12: “men vs. women: 1.88 (1.60-2.22)” should be “men vs. women: 1.79 (1.51-2.12)” Line 12: “current vs. non-smoking: 0.76 (0.63-0.91)” should be “current vs. non-smoking: 0.72 (0.59-0.87)” Line 12-13: “HLA-B27 positive vs. negative: 1.51 (1.20-1.91)” should be “HLA-B27 positive vs. negative: 1.65 (1.27-2.15)” Line 14: “CRP>10 vs. ≤10 mg/l: 1.49 (1.25-1.77)” should be “CRP>10 vs. ≤10 mg/l: 1.36 (1.14-1.62)” Line 15-16: “fatigue and spinal pain: 0.99 (0.99-1.00) and 0.99 (0.99-1.99)” should be “fatigue and spinal pain: 0.99 (0.99-0.99) and 0.99 (0.99-1.00)” In Table 3, row with EPV (row 3 after header/subheader): Column with header/subheader “Czech Republic/ATTRA”: EPV 15.9 should be 13.2 Column with header/subheader “Netherlands/ARC”: EPV 1 should be 1.0 Column with header/subheader “Portugal/Reuma.pt”: EPV 14.7 should be 13.1 Column with header/subheader “Romania/RRBR”: EPV 2.8 should be 2.4 Column with header/subheader “Turkey/TURKBIO”: EPV 12.9 should be 11.8 In Table 5, row with “Patient global score, mm” (row 10 counting from row with “Age at treatment start, years”): In the column with header: “Analysis of 12-month drug retention” and subheader: “Univariate”, the value for the odds ratio (OR) is missing. The OR should be 0.99. The authors would like to apologise for any inconvenience caused. © 2022 The Authors